PMA Perspectives Q1 2022

PMA Perspectives Q1 2021


Insights from pharmaceuticals, market access and Team Remap.

We hope you’ve had a wonderful start to the New Year and we’d love to welcome you to our fourth and final edition of Remap Perspectives 2021, where we’ll share the latest #TeamRemap news and a summary of our key blogs and articles from the past three months.

We hope you enjoy and if you have any thoughts on any of the articles or content shared today, please reach out.



Always on the lookout for ambitious and enthusiastic individuals, we’re currently recruiting for various positions including Analyst and Business Development Director.

Fancy a new challenge? Click on the links above for further information on these new exciting roles.


Prior to joining Remap Consulting Lauren gained experience working on a diverse range of healthcare projects in areas including rare disease, neurology and oncology.

Through her prior experience in the health and care sector, Lauren developed her understanding of challenges faced within the industry, such as the importance of knowledge dissemination and the influence of health policy in getting drugs to market.


Michael is an analyst with previous experience in client-focused roles, allowing him to be effective in assessing and understanding clients’ problems to provide the best solutions.

Michael gained valuable experience of the pharmaceutical industry and insight into the drug development process as well as extensive data analysis skills.


Our Senior Project Administrator Charlotte took part in the Tatton Yule Yomp last December. The 10k race is a 1-lap course that runs through and around Tatton Park, consisting of undulating terrain, trail, grass, tarmac and gravel. 

Charlotte raised a fantastic £280 for East Cheshire Hospice. The charity provides care, comfort and compassionate support to patients facing life-limiting illnesses and their loved ones.

We are extremely proud of her achievement and want to take this opportunity to say a huge thanks to all who have donated in 2021.


We presented three abstracts at ISPOR Europe’s Virtual Event between 1st – 3rd December 2021. We’ve published all three posters to our website – you can access via the links below.

Does Orphan Drug Status Confer Any Benefits for Products Undergoing HTA Appraisal By Nice in England?

Are Nice Becoming More Efficient in the Duration of the Highly-Specialised Technologies (HST) Process?

How Do the Pricing and Reimbursement Policies for Digital Therapeutics Compare and Contrast between the US, EU-5, China and Japan?


 What are the 5 Pricing & Market Access trends that will shape 2022?

The Challenges and Opportunities of the COVID-19 Pandemic: A Review at Two Years In

 Is Joe Biden’s Build Back Better Act the beginning of the end of higher drug prices in the US?

 How does NICE make cost effectiveness decisions on medicines and what are modifiers?

 High-cost oncology combination therapies are upon us – how can we evaluate them and make them more affordable?

 The product life cycle

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.